dc.contributor.author | Bafaloukos, Dimitrios | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.contributor.author | Fountzilas, George | en |
dc.contributor.author | Skarlos, Dimosthenis V. | en |
dc.contributor.author | Klouvas, G. D. | en |
dc.contributor.author | Makrantonakis, P. | en |
dc.contributor.author | Giannakakis, T. | en |
dc.contributor.author | Tsavaris, N. | en |
dc.contributor.author | Kosmidis, Paraskevas A. | en |
dc.creator | Bafaloukos, Dimitrios | en |
dc.creator | Pavlidis, Nicholas | en |
dc.creator | Fountzilas, George | en |
dc.creator | Skarlos, Dimosthenis V. | en |
dc.creator | Klouvas, G. D. | en |
dc.creator | Makrantonakis, P. | en |
dc.creator | Giannakakis, T. | en |
dc.creator | Tsavaris, N. | en |
dc.creator | Kosmidis, Paraskevas A. | en |
dc.date.accessioned | 2018-06-22T09:52:31Z | |
dc.date.available | 2018-06-22T09:52:31Z | |
dc.date.issued | 1996 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/41391 | |
dc.description.abstract | Thirty-four patients with advanced malignant melanoma were treated with recombinant alpha-interferon (IFN) and chemotherapy consisting of carboplatin, vinblastine, and bleomycin (CVB). CVB was given for four cycles and IFN for 1 year or until progression. Of the 34 analyzed patients. 17 (50%) achieved an objective response, including two complete (6%) and 15 partial responses (44%). Responses were noted in cutaneous, lymph node, and pulmonary sites, with a median time to disease progression of 5 months (range, 320 months). The median survival from onset of therapy was 8 months (range, 1-22 months) for the 34 patients. Ninety-four percent of the patients experienced flu-like symptoms and 82% fatigue or weakness. Leukopenia grade 3-4 was observed in four patients (12%). There were two toxicity-related deaths (6%); one from bleomycin-induced pneumonitis and one from neutropenic sepsis. It is concluded that the addition of IFN to CVB regimen, in this study, showed no apparent advantage on response rates, disease-free interval, or survival. The observed treatment-related mortality was unacceptably high. IFN administered as maintenance therapy following CVB confered no survival benefit. | en |
dc.language.iso | eng | en |
dc.source | American Journal of Clinical Oncology: Cancer Clinical Trials | en |
dc.subject | Article | en |
dc.subject | Bleomycin | en |
dc.subject | Human | en |
dc.subject | Vinblastine | en |
dc.subject | Humans | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Female | en |
dc.subject | Middle aged | en |
dc.subject | Cancer survival | en |
dc.subject | Carboplatin | en |
dc.subject | Chemotherapy | en |
dc.subject | Antineoplastic combined chemotherapy protocols | en |
dc.subject | Clinical article | en |
dc.subject | Clinical trial | en |
dc.subject | Fatigue | en |
dc.subject | Leukopenia | en |
dc.subject | Neutropenia | en |
dc.subject | Prospective studies | en |
dc.subject | Thrombocytopenia | en |
dc.subject | Pneumonia | en |
dc.subject | Melanoma | en |
dc.subject | Male | en |
dc.subject | Blood cell count | en |
dc.subject | Gastrointestinal symptom | en |
dc.subject | Interferon | en |
dc.subject | Interferon alfa-2a | en |
dc.subject | Intravenous drug administration | en |
dc.subject | Maintenance therapy | en |
dc.subject | Malignant melanoma | en |
dc.subject | Mortality | en |
dc.subject | Recombinant alpha2a interferon | en |
dc.subject | Sepsis | en |
dc.subject | Subcutaneous drug administration | en |
dc.title | Recombinant interferon ALFA-2A in combination with carboplatin, vinblastine, and bleomycin in the treatment of advanced malignant melanoma | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1097/00000421-199606000-00018 | |
dc.description.volume | 19 | |
dc.description.issue | 3 | |
dc.description.startingpage | 296 | |
dc.description.endingpage | 300 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |